Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Research and Development Expenses: $44.7 million in Q3 2024, including $5.6 million in noncash stock-based compensation. General and Administrative Expenses: $16.3 million in Q3 2024, including $7.8 million in noncash stock-based compensation. Net Loss: $66.3 million or 32 per share in Q3 2024. Noncash Stock-Based Compensation Expense: $13.4 million in Q3 2024. Noncash Impairment of Long-Lived Asset Expense: $10.7 million in Q3 2024. Expected Cash Burn for 2024: Approximately $200 million. Expected Full Year 2024 GAAP Operating Expenses: Approximately $300 million, including $60 million in noncash stock-based compensation. Warning! GuruFocus has detected 3 Warning Signs with ALLO. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Allogene Therapeutics Inc ( NASDAQ:ALLO ) is advancing its pivotal Phase 2 ALPHA3 trial for large B cell lymphoma, which could set a new standard for first-
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Allogene's Q3 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCSGlobeNewswire
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 11/13/24 - Form 8-K
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ALLO's page on the SEC website